Progression of Growth Factor Receptor Signaling Pathway in Endocrine-Resistant Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LICong , LIZhi-gao , RENYan-lü , PANGDa ,  CHENGShao-qiang

Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150040, Heilongjiang Province, China;

Corresponding author：

CHENGShao-qiang, Email: shaoqiangcheng@hotmail.com

Keywords：

Breast cancer; Endocrine therapy; Drug resistance; Growth factor receptor; Estrogen receptor

DOI：

10.7507/1007-9424.20160169

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize progression of growth factor receptor (GFR) signaling pathway in endocrineresistant breast cancer. Method Literatures about mechanisms of GFR signaling pathway in the development of endocrineresistant breast cancer were reviewed. Results The crosstalk between GFR and estrogen receptor (ER) signaling pathway had been reported to be involved in the development of endocrine-resistant breast cancer. Interrupting this signaling pathway could overcome endocrine therapy resistance. Many clinical trails had shown that the utilizing endocrine therapy combined with GFR inhibitors could obviously increase the survival rate of patients with breast cancer. Conclusion Several agents targeting GFR signaling pathways show a great potential for treatment of patients with breast cancer.

Citation： LICong, LIZhi-gao, RENYan-lü, PANGDa, CHENGShao-qiang. Progression of Growth Factor Receptor Signaling Pathway in Endocrine-Resistant Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(5): 626-630. doi: 10.7507/1007-9424.20160169 Copy

1.	DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin, 2014, 64(1):52-62.
2.	Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst, 1998, 90(11):814-823.
3.	Zhao M, Ramaswamy B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol, 2014, 5(3):248-262.
4.	Nilsson S, Gustafsson JA. Estrogen receptors:therapies targeted to receptor subtypes. Clin Pharmacol Ther, 2011, 89(1):44-55.
5.	Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer, 2011, 11(8):597-608.
6.	Frasor J, Danes JM, Komm B, et al. Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells:insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology, 2003, 144(10):4562-4574.
7.	Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids, 2000, 65(5):227-251.
8.	Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat, 2008, 108(3):351-361.
9.	Revankar CM, Cimino DF, Sklar LA, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 2005, 307(5715):1625-1630.
10.	Sachdev JC, Jahanzeb M. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin Breast Cancer, 2012, 12(1):19-29.
11.	Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifenresistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat, 1992, 24(2):85-95.
12.	Giordano C, Catalano S, Panza S, et al. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene, 2011, 30(39):4129-4140.
13.	Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology, 2003, 144(3):1032-1044.
14.	Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature, 2008, 456(7222):663-666.
15.	Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol, 2011, 29(33):4452-4461.
16.	Morelli C, Garofalo C, Bartucci M, et al. Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene, 2003, 22(26):4007-4016.
17.	Parisot JP, Leeding KS, Hu XF, et al. Induction of insulin-like growth factor binding protein expression by ICI 182780 in a tamoxifen-resistant human breast cancer cell line. Breast Cancer Res Treat, 1999, 55(3):231-242.
18.	Lisztwan J, Pornon A, Chen B, et al. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factorⅠreceptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res, 2008, 10(4):R56.
19.	Milano A, Dal Lago L, Sotiriou C, et al. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer, 2006, 42(16):2692-2705.
20.	Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev, 2014, 40(7):862-871.
21.	Provenzano A, Kurian S, Abraham J. Overcoming endocrine resistance in breast cancer:role of the PI3K and the mTOR pathways. Expert Rev Anticancer Ther, 2013, 13(2):143-147.
22.	Creighton CJ, Fu X, Hennessy BT, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+breast cancer. Breast Cancer Res, 2010, 12(3):R40.
23.	Chen X, Zhao M, Hao M, et al. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Mol Cancer Res, 2013, 11(10):1269-1278.
24.	Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 2014, 507(7492):315-322.
25.	Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med, 2011, 62:233-247.
26.	Brodie A, Jelovac D, Sabnis G, et al. Model systems:mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol, 2005, 95(5):41-48.
27.	Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer:results from the randomized phaseⅢTAnDEM study. J Clin Oncol, 2009, 27(33):5529-5537.
28.	Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer-results of the eLEcTRA trial. Breast, 2012, 21(1):27-33.
29.	Cristofanilli M, Valero V, Mangalik A, et al. PhaseⅡ, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res, 2010, 16(6):1904-1914.
30.	Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 2009, 27(33):5538-5546.
31.	Mayer IA, Abramson VG, Isakoff SJ, et al. Stand up to cancer phaseⅠb study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol, 2014, 32(12):1202-1209.
32.	Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-classⅠPI3-kinase inhibitor. Mol Cancer Ther, 2012, 11(2):317-328.
33.	Bachelot T, Bourgier C, Cropet C, et al. Randomized phaseⅡtrial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors:a GINECO study. J Clin Oncol, 2012, 30(22):2718-2724.
34.	Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 2012, 366(6):520-529.
35.	Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phaseⅢplacebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol, 2013, 31(2):195-202.
36.	Robertson JF, Ferrero JM, Bourgeois H, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer:a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol, 2013, 14(3):228-235.

1. DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin, 2014, 64(1):52-62.
2. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst, 1998, 90(11):814-823.
3. Zhao M, Ramaswamy B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol, 2014, 5(3):248-262.
4. Nilsson S, Gustafsson JA. Estrogen receptors:therapies targeted to receptor subtypes. Clin Pharmacol Ther, 2011, 89(1):44-55.
5. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer, 2011, 11(8):597-608.
6. Frasor J, Danes JM, Komm B, et al. Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells:insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology, 2003, 144(10):4562-4574.
7. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids, 2000, 65(5):227-251.
8. Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat, 2008, 108(3):351-361.
9. Revankar CM, Cimino DF, Sklar LA, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 2005, 307(5715):1625-1630.
10. Sachdev JC, Jahanzeb M. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin Breast Cancer, 2012, 12(1):19-29.
11. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifenresistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat, 1992, 24(2):85-95.
12. Giordano C, Catalano S, Panza S, et al. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene, 2011, 30(39):4129-4140.
13. Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology, 2003, 144(3):1032-1044.
14. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature, 2008, 456(7222):663-666.
15. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol, 2011, 29(33):4452-4461.
16. Morelli C, Garofalo C, Bartucci M, et al. Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene, 2003, 22(26):4007-4016.
17. Parisot JP, Leeding KS, Hu XF, et al. Induction of insulin-like growth factor binding protein expression by ICI 182780 in a tamoxifen-resistant human breast cancer cell line. Breast Cancer Res Treat, 1999, 55(3):231-242.
18. Lisztwan J, Pornon A, Chen B, et al. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factorⅠreceptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res, 2008, 10(4):R56.
19. Milano A, Dal Lago L, Sotiriou C, et al. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer, 2006, 42(16):2692-2705.
20. Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev, 2014, 40(7):862-871.
21. Provenzano A, Kurian S, Abraham J. Overcoming endocrine resistance in breast cancer:role of the PI3K and the mTOR pathways. Expert Rev Anticancer Ther, 2013, 13(2):143-147.
22. Creighton CJ, Fu X, Hennessy BT, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+breast cancer. Breast Cancer Res, 2010, 12(3):R40.
23. Chen X, Zhao M, Hao M, et al. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Mol Cancer Res, 2013, 11(10):1269-1278.
24. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 2014, 507(7492):315-322.
25. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med, 2011, 62:233-247.
26. Brodie A, Jelovac D, Sabnis G, et al. Model systems:mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol, 2005, 95(5):41-48.
27. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer:results from the randomized phaseⅢTAnDEM study. J Clin Oncol, 2009, 27(33):5529-5537.
28. Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer-results of the eLEcTRA trial. Breast, 2012, 21(1):27-33.
29. Cristofanilli M, Valero V, Mangalik A, et al. PhaseⅡ, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res, 2010, 16(6):1904-1914.
30. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 2009, 27(33):5538-5546.
31. Mayer IA, Abramson VG, Isakoff SJ, et al. Stand up to cancer phaseⅠb study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol, 2014, 32(12):1202-1209.
32. Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-classⅠPI3-kinase inhibitor. Mol Cancer Ther, 2012, 11(2):317-328.
33. Bachelot T, Bourgier C, Cropet C, et al. Randomized phaseⅡtrial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors:a GINECO study. J Clin Oncol, 2012, 30(22):2718-2724.
34. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 2012, 366(6):520-529.
35. Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phaseⅢplacebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol, 2013, 31(2):195-202.
36. Robertson JF, Ferrero JM, Bourgeois H, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer:a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol, 2013, 14(3):228-235.

Previous Article
Progression of Diagnosis and Treatment of Medullary Thyroid Carcinoma
Next Article
Progress of Minimally Invasive Diagnosis and Treatment of Patients with Choledocholithiasis

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Progression of Growth Factor Receptor Signaling Pathway in Endocrine-Resistant Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content